Benitec Biopharma Executes Research Collaboration with Nant Capital

Biotech Investing

Benitec Biopharma Limited (ASX:BLT,NASDAQ:BNTC,NASDAQ:BNTCW) has executed a Research Collaboration Agreement with Nant Capital, and has initiated work on two new oncology pipeline programs. As quoted in the press release: Under the terms of the executed Research Collaboration Agreement, Benitec has taken control of the clinical development of BB-401, a recombinant DNA construct that produces an …

Under the terms of the executed Research Collaboration Agreement, Benitec has taken control of the
clinical development of BB-401, a recombinant DNA construct that produces an antisense RNA with
specificity against Epidermal Growth Factor Receptor (EGFR). This clinically validated molecular target
is overexpressed in up to 90% of all HNSCC. According to GlobalData (Head and Neck Squamous Cell
Carcinoma – Opportunity Analysis and Forecast to 2024, February 2016), approximately 64,000 new
patients will be diagnosed annually in the US with HNSCC and 50% of the patients are expected to
develop recurrent or metastatic disease, with approximately 13,000 annual deaths expected in the US
from HNSCC.

Click here for the full press release.

benitec biopharma biopharma dna oncology pipeline rna Biotech Investing